1-Pyrrolidinecarboxylic Acid, 2-(Cyanomethyl)-, 1,1-Dimethylethyl Ester, (2S)-

The catalytic hydrogenation stage within the production sequence for the atypical antipsychotic agent levosulpiride utilises (2S)-2-(cyanomethyl)-1-pyrrolidinecarboxylic acid 1,1-dimethylethyl ester as the immediate precursor to the chiral amine fragment. In a 500-L Hastelloy C-22 high-pressure autoclave fitted with a cavity-tuned gas-induction impeller, the nitrile is dissolved in methanol containing 7 N ammonia (to suppress secondary amine formation via Schiff-base condensation) and hydrogenated over 5% Pd/C (50% water-wet, 0.05 molar eq. Pd) at 45 °C and a constant hydrogen pressure of 4.0 bar. The addition proportion of the Boc-protected nitrile relative to the target aminomethyl hydrochloride salt is 1.00 eq.; catalyst loading is calibrated such that the reaction exotherm does not exceed an adiabatic temperature rise of 12 °C—crossing 55 °C initiates measurable racemisation at the C-2 stereocentre, as confirmed by circular dichroism on-line monitoring. Termination of hydrogen uptake is determined by in-situ ReactIR tracking of the ν(C≡N) band at 2245 cm⁻¹ disappearing below a limit of detection equivalent to 0.15% residual nitrile. The post-hydrogenation slurry is filtered through a 0.5-µm sintered metal candle filter to recover catalyst, and the filtrate is concentrated to a thick oil; the Boc-amine is then treated with 1.25 eq. of HCl in ethyl acetate at 0–5 °C to cleave the tert-butyloxycarbonyl group, precipitating (S)-2-(aminomethyl)pyrrolidine dihydrochloride. After recrystallisation from isopropanol/water (9:1 v/v), the intermediate is N-ethylated with bromoethane under Schotten-Baumann-type conditions (pH 9.5 ± 0.3) to yield the key chiral synthon for levosulpiride. The final API must comply with the European Pharmacopoeia monograph for Levosulpiride (EP 10.5, 01/2022:2648), which mandates enantiomeric purity ≥ 99.0% by chiral HPLC on a Chiralpak AD-H column (250 × 4.6 mm, 5 µm); residual palladium is controlled to ≤ 10 ppm per ICH Q3D, and benzene, a known impurity from bromoethane manufacturing, must be limited to ≤ 2 ppm per ICH Q3C Option 2. The terminal dosage forms are tablets containing 25 mg, 50 mg, or 100 mg of levosulpiride free base.

Spin-Labile Nitrile Intermediates in Constrained Bicyclic DPP-4 Inhibitor Analogues

Conversion of the (2S)-N-Boc-2-(cyanomethyl)pyrrolidine scaffold into a glycinamide-type DPP-4 inhibitor fragment proceeds through a tandem cyanide hydrolysis–amide coupling sequence executed on a 200-L glass-lined reactor train. The nitrile is first hydrated to the primary amide using 30% H₂O₂ (1.5 eq.) in ethanolic potassium carbonate at 40 °C for 6 h; quenching with sodium sulfite is mandatory to eliminate residual peroxide before the subsequent Boc-deprotection step. After solvent exchange to dichloromethane, the Boc group is removed with trifluoroacetic acid (2.0 eq.) in the presence of triisopropylsilane (4.0 eq.) as a tert-cation scavenger—omission of the scavenger results in diastereomeric alkylation of the pyrrolidine nitrogen, generating a persistent impurity that is not resolved by silica gel chromatography. The free amine is then coupled with a pre-activated Fmoc-L-proline pentafluorophenyl ester at a stoichiometric ratio of 1.00:1.05 (amine:active ester) under N-methylmorpholine buffering in dimethylformamide. Regulatory oversight follows ICH Q7 for GMP intermediate production, with in-process controls for residual dichloromethane (≤600 ppm, USP <467> Procedure A) and trifluoroacetic acid (≤1.0% w/w by ion chromatography). The target candidate molecule, a conformationally restricted dipeptide mimetic, is intended for further preclinical investigation; enantiomeric purity of the key intermediate is held at ≥ 98.5% by SFC on a Chiralpak IC column (4.6 × 150 mm, 3 µm) using the European Pharmacopoeia General Chapter 2.2.28 for enantiomeric purity determination.

Scaffold decoration of the macrocyclic core in next-generation HCV NS3/4A protease inhibitors frequently employs the (2S)-2-(cyanomethyl)pyrrolidine unit as a proline isostere, where the nitrile group undergoes late-stage [3+2] cycloaddition with azides generated in situ from resin-bound tripeptides. The process chemists at contract manufacturing organisations have reported that handling the free azide intermediate in bulk solution is avoided by generating it directly on the solid phase; subsequent dipolar cycloaddition with the nitrile moiety of the (2S)-N-Boc-2-(cyanomethyl)pyrrolidine fragment, catalyzed by 0.05 eq. of CuI and 0.10 eq. of tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) in acetonitrile/water (3:1) at 35 °C, furnishes the triazole-linked macrocycle precursor. The addition level of the Boc-protected nitrile building block is adjusted to 1.10 eq. relative to the resin loading to drive the cycloaddition to completion within 4 h. After cleavage from the resin, the product is purified by preparative HPLC on a C18 column; residual copper must be measured by atomic absorption spectroscopy and maintained below 10 ppm in compliance with ICH Q3D for parenteral drug substances. The downstream manufacturing of the final API—a macrocyclic HCV protease inhibitor—additionally includes a palladium-mediated hydrogenolysis step to remove a Cbz protecting group, requiring a second metal scavenging treatment with a functionalized silica gel column to ensure that both Pd and Cu concentrations meet the limits of the USP <232>/<233> elemental impurities procedures. The finished dosage form is typically a film-coated tablet combined with other direct-acting antiviral agents.

What Parameters Govern the Irreversible N-Alkylation Side Reaction During the Assembly of Factor Xa Inhibitors?

When the Boc-deprotected (2S)-2-(aminomethyl)pyrrolidine intermediate is advanced into the synthesis of pyrrolidine-based direct Factor Xa inhibitors, the amide coupling step with a 4-methoxyphenylpiperazine-activated ester is accompanied by a well-characterized side reaction: intramolecular O-to-N alkyl migration of the tert-butyl group released during acidic cleavage. In production campaigns conducted in a 100-L Hastelloy C-276 reactor, the free amine dihydrochloride salt is generated via treatment with 4 M HCl in dioxane (3.0 vol) containing 5% w/w anisole as a carbocation trap; without the anisole, N-tert-butyl-2-(aminomethyl)pyrrolidine forms at 0.8–1.2% area by HPLC and co-elutes with the API under conventional reversed-phase conditions, rendering the batch nonconformant. The coupling itself employs O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) and N,N-diisopropylethylamine at a stoichiometry of 1.00 eq. amine: 1.10 eq. acid: 1.20 eq. HBTU in dichloromethane at −10 °C, a temperature that is maintained within ±2 °C through jacket circulation of silicon oil to suppress racemisation. Regulatory compliance is anchored to ICH M7 for the assessment of mutagenic impurities, because the N-tert-butyl impurity triggers a structural alert (alkylating amine) in SAR analysis; its acceptable intake is calculated as 15 µg/day based on a 10⁻⁵ lifetime cancer risk. The final API is isolated as a crystalline hemi-fumarate salt, and its powder X-ray diffraction pattern must match the reference standard of the respective Factor Xa inhibitor crystalline form, which is released as a 10 mg or 20 mg immediate-release tablet.

When the Cyanomethyl Functionality Is Hydrated to a Primary Amide in the Manufacture of Cathepsin K Inhibitor Candidates

Process development for a cathepsin K inhibitor candidate that incorporates the (2S)-2-(cyanomethyl)pyrrolidine motif as the P2 element relies on a carefully controlled nitrile hydrolysis to the corresponding primary amide without over-oxidation to the carboxylic acid. The transformation is carried out in a jacketed 50-L glass reactor equipped with a retreat-curve impeller and a PTFE-sealed pH probe. The substrate is dissolved in dimethyl sulfoxide (6.0 vol), and 28% aqueous hydrogen peroxide (1.05 eq.) is added simultaneously with 1 M aqueous potassium hydroxide via two peristaltic pumps to maintain the reaction pH at 9.0 ± 0.2 and the temperature at 25 ± 1 °C; excursions above 27 °C initiate the formation of the corresponding pyrrolidine-2-acetic acid, which is detectable by LC-MS as a [M+H]+ signal at an m/z shift of +1 relative to the amide and must be kept below 0.10% area. The addition ratio of the nitrile is 1.00 eq., and the hydrogen peroxide charge is limited to 1.05 eq. to minimise residual oxidant. After 3 h of ageing, the batch is quenched with 10% w/v aqueous sodium metabisulfite until a negative starch-iodide test is obtained. Subsequent Boc-deprotection with 4 M HCl in ethyl acetate and coupling with a benzonitrile-based P1 fragment completes the backbone of the inhibitor. The isolated hydrochloride salt is controlled for residual solvents by headspace GC per USP <467> with special attention to dimethyl sulfoxide (≤5000 ppm) and ethyl acetate (≤5000 ppm); the final API intermediate is shipped to a dedicated GMP suite for capping to the active pharmaceutical ingredient, which is formulated into a 25 mg once-weekly tablet for bone resorption disorders.